EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference

Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced that CEO Nancy Lurker will participate in a fireside chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 9:30 am ET. The event will be accessible via a live webcast and an archived replay on the Investors section of the Company's website, available for 90 days post-event. EyePoint specializes in therapeutics for serious eye disorders, notably using its Durasert® technology for sustained drug delivery, with products like YUTIQ® and the pipeline candidate EYP-1901 targeting wet age-related macular degeneration.

WATERTOWN, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022 at 9:30 am ET.

A live webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When will Nancy Lurker participate in the B. Riley 2022 conference?

Nancy Lurker will participate in the B. Riley 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 9:30 am ET.

What is EYPT's Durasert® technology?

EYPT's Durasert® technology is a proprietary method for sustained intraocular drug delivery, used in several approved products and pipeline therapies.

How can I access the replay of the fireside chat?

The replay of the fireside chat can be accessed in the Investors section of EyePoint Pharmaceuticals' website for 90 days after the event.

What are the applications of EyePoint's therapeutics?

EyePoint Pharmaceuticals focuses on therapeutics for serious eye disorders, including treatments like EYP-1901 for wet age-related macular degeneration.

What products has EyePoint Pharmaceuticals developed?

EyePoint has developed products including YUTIQ® for chronic non-infectious uveitis, leveraging its Durasert® drug delivery technology.